small cell lung cancer (SCLC)
Conditions
Interventions
Group A:Subject to standard treatment regimen of atezolizumab + carboplatin/cisplatin + etoposide
Group B:Standard chemotherapy regimen of carboplatin/cisplatin + etoposide
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with extensive-stage small cell lung cancer treated in our department since January 2019; 2. Aged 18-80 years, or those who are expected to survive naturally for more than 3 months; 3. Histology/cytology confirmed small cell lung cancer, and staging examination confirmed that the disease was staged as extensive stage (according to the modified American Veterans Administration Lung Cancer Association [VALG] staging system); 4. The ECOG physical condition score is less than or equal to 2 points; 5. Have not received systemic treatment for diagnosis of ES-SCLC before; 6. For patients who have received radiotherapy and chemotherapy for limited-stage SCLC in the past: the treatment must be for the purpose of cure, and between the last dose/last course of chemotherapy, the end of chest radiotherapy or radiotherapy and chemotherapy and the diagnosis of ES-SCLC, have a treatment-free interval of at least 6 months; 7. According to RECIST v1.1, there are measurable lesions; 8. Patients received carboplatin/cisplatin + etoposide ± atezolizumab regimen.
Exclusion criteria
Exclusion criteria: 1. Complete clinical diagnosis and treatment information cannot be provided. 2. Previous treatment with immune checkpoint inhibitors other than atezolizumab. 3. Patients who have received radiotherapy for target lesions (can receive palliative radiotherapy for non-target lesions for symptom control).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression-free survival;Adverse events; | — |
Countries
China
Contacts
Public ContactZhuo Minglei
Beijing Cancer Hospital
Outcome results
None listed